FI111951B - (3aS)-5,5-diokso-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]bentsotiadiatsiini S-enantiomeerinsä muodossa, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset - Google Patents

(3aS)-5,5-diokso-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]bentsotiadiatsiini S-enantiomeerinsä muodossa, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset Download PDF

Info

Publication number: FI111951B
Authority: FI; Finland
Prior art keywords: formula; compound; medium; med; preparation
Prior art date: 1994-07-12

Application number

FI953384A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI953384A0 (fi

FI953384L (fi

Inventor

Alex Cordi

Michael Spedding

Bernard Serkiz

Jean Lepagnol

Patrice Desos

Philippe Morain

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-12

Filing date

1995-07-11

Publication date

2003-10-15

1995-07-11 Application filed by Servier Lab filed Critical Servier Lab

1995-07-11 Publication of FI953384A0 publication Critical patent/FI953384A0/fi

1996-01-13 Publication of FI953384L publication Critical patent/FI953384L/fi

2003-10-15 Application granted granted Critical

2003-10-15 Publication of FI111951B publication Critical patent/FI111951B/fi

Links

150000001875 compounds Chemical class 0.000 title claims description 42
238000000034 method Methods 0.000 title claims description 13
230000008569 process Effects 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
MNTIJYGEITVWHU-SNVBAGLBSA-N (3as)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C12=CC=CC=C2S(=O)(=O)N[C@@H]2N1CCC2 MNTIJYGEITVWHU-SNVBAGLBSA-N 0.000 title abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 5
230000005062 synaptic transmission Effects 0.000 claims description 5
239000012279 sodium borohydride Substances 0.000 claims description 4
229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
QRKDOAWSBBGNLE-UHFFFAOYSA-N 2h-1,2,4-benzothiadiazine Chemical compound C1=CC=C2N=CNSC2=C1 QRKDOAWSBBGNLE-UHFFFAOYSA-N 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
230000001575 pathological effect Effects 0.000 claims description 3
238000000746 purification Methods 0.000 claims description 3
201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
230000001476 alcoholic effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
230000004770 neurodegeneration Effects 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
206010002869 Anxiety symptoms Diseases 0.000 claims 2
230000000750 progressive effect Effects 0.000 claims 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
206010008748 Chorea Diseases 0.000 claims 1
206010054089 Depressive symptom Diseases 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 claims 1
208000012601 choreatic disease Diseases 0.000 claims 1
239000003086 colorant Substances 0.000 claims 1
238000004040 coloring Methods 0.000 claims 1
230000003001 depressive effect Effects 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
230000004064 dysfunction Effects 0.000 claims 1
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 claims 1
208000019622 heart disease Diseases 0.000 claims 1
230000001771 impaired effect Effects 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
230000000626 neurodegenerative effect Effects 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
239000006188 syrup Substances 0.000 claims 1
235000020357 syrup Nutrition 0.000 claims 1
238000004809 thin layer chromatography Methods 0.000 claims 1
239000000203 mixture Substances 0.000 description 10
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
102000003678 AMPA Receptors Human genes 0.000 description 8
108090000078 AMPA Receptors Proteins 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000000287 oocyte Anatomy 0.000 description 5
ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 4
229960000793 aniracetam Drugs 0.000 description 4
230000002964 excitative effect Effects 0.000 description 4
229930195712 glutamate Natural products 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000000243 solution Substances 0.000 description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
QUTYKIXIUDQOLK-PRJMDXOYSA-N 5-O-(1-carboxyvinyl)-3-phosphoshikimic acid Chemical compound O[C@H]1[C@H](OC(=C)C(O)=O)CC(C(O)=O)=C[C@H]1OP(O)(O)=O QUTYKIXIUDQOLK-PRJMDXOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
241000269370 Xenopus <genus> Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
229960004042 diazoxide Drugs 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
238000004452 microanalysis Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
101000768857 Arabidopsis thaliana 3-phosphoshikimate 1-carboxyvinyltransferase, chloroplastic Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000002461 excitatory amino acid Effects 0.000 description 2
239000003257 excitatory amino acid Substances 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
HWOJZNGWXRYGBY-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C12=CC=CC=C2S(=O)(=O)N=C2N1CCC2 HWOJZNGWXRYGBY-UHFFFAOYSA-N 0.000 description 1
YAZSBRQTAHVVGE-UHFFFAOYSA-N 2-aminobenzenesulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O YAZSBRQTAHVVGE-UHFFFAOYSA-N 0.000 description 1
HCMQCNNTMBBVLX-UHFFFAOYSA-N 2-aminobenzenesulfonyl chloride Chemical compound NC1=CC=CC=C1S(Cl)(=O)=O HCMQCNNTMBBVLX-UHFFFAOYSA-N 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000036626 alertness Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
-1 benzothiadiazine compound Chemical class 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
230000000059 bradycardiac effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000036749 excitatory postsynaptic potential Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000006386 memory function Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000933 neural crest Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
150000002913 oxalic acids Chemical class 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

FI953384A 1994-07-12 1995-07-11 (3aS)-5,5-diokso-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]bentsotiadiatsiini S-enantiomeerinsä muodossa, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset FI111951B (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9408603		1994-07-12
FR9408603A FR2722502B1 (fr)	1994-07-12	1994-07-12	Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent

Publications (3)

Publication Number	Publication Date
FI953384A0 FI953384A0 (fi)	1995-07-11
FI953384L FI953384L (fi)	1996-01-13
FI111951B true FI111951B (fi)	2003-10-15

Family

ID=9465275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI953384A FI111951B (fi)	1994-07-12	1995-07-11	(3aS)-5,5-diokso-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]bentsotiadiatsiini S-enantiomeerinsä muodossa, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset

Country Status (17)

Country	Link
US (1)	US5536719A (el)
EP (1)	EP0692484B1 (el)
JP (1)	JP3159894B2 (el)
CN (1)	CN1043645C (el)
AT (1)	ATE178332T1 (el)
AU (1)	AU684367B2 (el)
CA (1)	CA2153549C (el)
CY (1)	CY2161B1 (el)
DE (1)	DE69508667T2 (el)
DK (1)	DK0692484T3 (el)
ES (1)	ES2132556T3 (el)
FI (1)	FI111951B (el)
FR (1)	FR2722502B1 (el)
GR (1)	GR3029847T3 (el)
NO (1)	NO306116B1 (el)
NZ (1)	NZ272543A (el)
ZA (1)	ZA955793B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2206604T3 (es) *	1995-11-15	2004-05-16	Yamanouchi Pharmaceutical Co., Ltd.	Inhibidores de la neurotoxicidad del acido kainico y derivados de la piridotiazina.
SK11892000A3 (sk) *	1998-02-18	2001-02-12	Neurosearch A/S	Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora
US6943159B1 (en)	1998-02-18	2005-09-13	Neurosearch A/S	Compounds and their use as positive AMPA receptor modulators
FR2812291B1 (fr) *	2000-07-28	2002-12-13	Adir	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2823753B1 (fr) *	2001-04-18	2004-07-16	Servier Lab	Nouveau procede de synthese de la (3as)-5,5-dioxo-2,3,3a, 4-tetrahydro-1h-pyrrolo [2,1-c] [1,2,4] benzothiadiazine
ITBO20010271A1 (it) *	2001-05-08	2002-11-08	Giuseppe Cannazza	Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl
FR2833955B1 (fr)	2001-12-21	2004-01-30	Servier Lab	Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833956B1 (fr) *	2001-12-21	2004-01-30	Servier Lab	Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2856065B1 (fr) *	2003-06-13	2005-08-19	Servier Lab	Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2856064B1 (fr) *	2003-06-13	2005-08-19	Servier Lab	Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2877342B1 (fr)	2004-11-03	2007-01-26	Servier Lab	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877338B1 (fr)	2004-11-03	2007-01-26	Servier Lab	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr)	2004-12-10	2007-02-16	Servier Lab	Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2933698A1 (fr)	2008-07-09	2010-01-15	Servier Lab	Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2955106B1 (fr)	2010-01-08	2011-12-23	Servier Lab	Nouveaux derives de benzothiadiazines cyclopropylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2955107B1 (fr)	2010-01-08	2012-03-02	Servier Lab	Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

1994
- 1994-07-12 FR FR9408603A patent/FR2722502B1/fr not_active Expired - Fee Related
1995
- 1995-07-10 CA CA002153549A patent/CA2153549C/fr not_active Expired - Fee Related
- 1995-07-10 AU AU24913/95A patent/AU684367B2/en not_active Ceased
- 1995-07-11 CN CN95109986A patent/CN1043645C/zh not_active Expired - Fee Related
- 1995-07-11 FI FI953384A patent/FI111951B/fi active
- 1995-07-11 NZ NZ272543A patent/NZ272543A/en not_active IP Right Cessation
- 1995-07-11 NO NO952743A patent/NO306116B1/no not_active IP Right Cessation
- 1995-07-11 US US08/500,609 patent/US5536719A/en not_active Expired - Lifetime
- 1995-07-12 AT AT95401666T patent/ATE178332T1/de not_active IP Right Cessation
- 1995-07-12 EP EP95401666A patent/EP0692484B1/fr not_active Expired - Lifetime
- 1995-07-12 DE DE69508667T patent/DE69508667T2/de not_active Expired - Fee Related
- 1995-07-12 ES ES95401666T patent/ES2132556T3/es not_active Expired - Lifetime
- 1995-07-12 JP JP17585095A patent/JP3159894B2/ja not_active Expired - Fee Related
- 1995-07-12 DK DK95401666T patent/DK0692484T3/da active
- 1995-07-12 ZA ZA955793A patent/ZA955793B/xx unknown
1999
- 1999-04-05 GR GR990400935T patent/GR3029847T3/el unknown
2000
- 2000-03-01 CY CY0000004A patent/CY2161B1/xx unknown

Also Published As

Publication number	Publication date
JPH0841072A (ja)	1996-02-13
JP3159894B2 (ja)	2001-04-23
ZA955793B (en)	1996-03-05
DK0692484T3 (da)	1999-10-18
NO952743D0 (no)	1995-07-11
ES2132556T3 (es)	1999-08-16
CY2161B1 (en)	2002-08-23
DE69508667D1 (de)	1999-05-06
CA2153549C (fr)	2003-07-08
CA2153549A1 (fr)	1996-01-13
ATE178332T1 (de)	1999-04-15
EP0692484A1 (fr)	1996-01-17
FI953384A0 (fi)	1995-07-11
FI953384L (fi)	1996-01-13
AU684367B2 (en)	1997-12-11
EP0692484B1 (fr)	1999-03-31
DE69508667T2 (de)	1999-10-28
CN1121921A (zh)	1996-05-08
NO952743L (no)	1996-01-15
GR3029847T3 (en)	1999-07-30
NZ272543A (en)	1996-04-26
CN1043645C (zh)	1999-06-16
FR2722502B1 (fr)	1996-08-23
NO306116B1 (no)	1999-09-20
US5536719A (en)	1996-07-16
FR2722502A1 (fr)	1996-01-19
AU2491395A (en)	1996-01-25

Publication	Publication Date	Title
FI111951B (fi)	2003-10-15	(3aS)-5,5-diokso-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]bentsotiadiatsiini S-enantiomeerinsä muodossa, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset
US5519019A (en)	1996-05-21	N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
Neumeyer et al.	1992	Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7, 8-dihydroxy-1-phenyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine and its 6-bromo analog
US5521174A (en)	1996-05-28	N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
JP4461139B2 (ja)	2010-05-12	チアジアジン誘導体及びポジティブａｍｐａ受容体モジュレーターとしてのそれらの使用
JP3643325B2 (ja)	2005-04-27	新規なベンゾチアジアジン化合物、その製造方法およびそれを含有する医薬組成物
JP2005002114A (ja)	2005-01-06	新規なベンゾチアジンおよびベンゾチアジアジン化合物、それらの製造方法、ならびにそれらを含む医薬組成物
Baindur et al.	1992	(.+-.)-3-Allyl-7-halo-8-hydroxy-1-phenyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepines as selective high affinity D1 dopamine receptor antagonists: synthesis and structure-activity relationship
CA2350560C (en)	2006-10-31	Novel type condensed pyridazinone compounds
JPH02191272A (ja)	1990-07-27	１，５―ベンゾオキサチエピン誘導体
JP2004529980A (ja)	2004-09-30	正のアロステリックａｍｐａレセプターモジュレーター（ｐａａｒｍ）であるナフトチアジン化合物
Robaa	2011	Novel Benzindoloazecines and Dibenzazecines: Synthesis and Affinities for the Dopamine Receptors
Fattah et al.	2013	Modulating Dopamine Receptors Subtype Selectivity by Thiophene and Benzothiophene based Derivatives
Abdel-Fattah	2013	Modulating dopamine receptors subtype selectivity by thiophene and benzothiophene based derivatives
HK1088327B (en)	2008-05-02	Thiadiazine derivatives and use thereof as positive ampa receptor modulators
HK1068792A1 (zh)	2005-05-06	用作5-ht6和/或5-ht7 5-羥色胺受體的配體的5-鹵代-色胺衍生物
HK1068792B (en)	2009-12-31	5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors